gavilimomab gavilimomab gavilimomab (also known as abx-cbl) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. it binds to the antigen cd147. gavilimomab proved slightly less effective than standard antithymocyte globulin therapy. gavilimomabmonoclonal antibodytypewhole antibodysourcemousetargetcd147clinical dataatc codenoneidentifierscas number244096-20-6 nchemspidernoneuniitcr92293rc ny (what is this?) (verify) it was originally developed by abgenix, which was later acquired by amgen.